Olivier Molinier - Researcher Profile

Publications

3 shown

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Filippo de Marinis , Mircea Dediu +14 more

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0....

2013 Journal of Clinical Oncology 626 citations

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

M. Pérol , Clarisse Audigier-Valette , Olivier Molinier +17 more

9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be larger for continuatio...

2017 Journal of Clinical Oncology 6 citations

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares , Filippo de Marinis , Mircea Dediu +14 more

2012 The Lancet Oncology 605 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 1,237
Institution: Heidelberg University

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-7965-2989

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.